{"schema_version":"secwatch.filing_event.v1","accession":"0001664710-24-000058","form_type":"8-K","ticker":"KROS","cik":"0001664710","company_name":"Keros Therapeutics, Inc.","filed_at":"2024-06-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.492494+00:00","generated_at":"2026-06-01T04:07:21.948418+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Keros CEO Seehra becomes Chair; Rovaldi promoted to President effective July 1","bullets":["CEO Jasbir Seehra appointed Chair of Board, effective July 1, 2024, succeeding Carl Gordon who remains director.","Christopher Rovaldi promoted to President in addition to COO, effective July 1, 2024, replacing Seehra as President.","Jean-Jacques Bienaimé appointed Lead Independent Director, effective July 1, with a new $25,000 annual retainer.","Leadership changes come as Keros prepares for first registrational Phase 3 trial of elritercept (KER-050)."],"urls":{"canonical":"https://secwatch.observer/filing/0001664710-24-000058","json":"https://secwatch.observer/filing/0001664710-24-000058.json","markdown":"https://secwatch.observer/filing/0001664710-24-000058.md","text":"https://secwatch.observer/filing/0001664710-24-000058.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1664710/000166471024000058/0001664710-24-000058-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1664710/000166471024000058/kros-20240614.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T04:07:21.948418+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"07a6b7da01","claim":"Carl L. Gordon resigned as Chair of the Board at Keros Therapeutics, Inc..","evidence_excerpt":"Carl L. Gordon currently serves as the Chair of the Board and, effective June 30, 2024, will resign from such position and serve as a member of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1664710/000166471024000058/0001664710-24-000058-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chair of the Board"}],"fact_type":"executive_change"},{"claim_id":"8a098c45d9","claim":"Jean-Jacques Bienaimé was appointed as Lead Independent Director at Keros Therapeutics, Inc..","evidence_excerpt":"the Board appointed Jean-Jacques Bienaimé as Lead Independent Director, effective July 1, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1664710/000166471024000058/0001664710-24-000058-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Lead Independent Director"}],"fact_type":"executive_change"},{"claim_id":"f508fa0261","claim":"Christopher Rovaldi was appointed as President and Chief Operating Officer at Keros Therapeutics, Inc..","evidence_excerpt":"The Board appointed Christopher Rovaldi to the additional position as the Company’s President, effective July 1, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1664710/000166471024000058/0001664710-24-000058-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}